Moreover, aberrant VDAC2 expression or functioning has been reported in multiple tumors, including melanoma, epithelial thyroid tumors, and breast cancer, indicating that targeting VDAC2 is of therapeutic significance for cancer treatment37–39. Here, VDAC2 is linked to breast cancer.